Adagene (ADAG)

• Market cap: $85.9M
• 1 day: 0.00%
• 5 days: -6.73%
• 1 month: -23.32%
• 3 months: -10.19%
• 6 months: -29.71%
• Year to date: -5.83%
• 1 year: -29.20%
• 5 years: -93.53%
• 10 years: -93.53%

About: Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.

Employees: 174

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0.19% more ownership

Funds ownership: 20.5% [Q2] → 20.69% (+0.19%) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

7% less funds holding

Funds holding: 14 [Q2] → 13 (-1) [Q3]

24% less capital invested

Capital invested by funds: $34M [Q2] → $25.9M (-$8.09M) [Q3]

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4